Premium
Alnylam Pharmace Dl 0001 (0HD2)
LSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-13 | Ms. Amy W. SchulmanIndependent Chair of the Board | 11,25k | 789,75k | Derivative Exercise and Retained Stock | 70,20 | 23,21k | 94,06% |
| 2026-04-06 | Ms. Melissa McLaughlinChief HR Officer | -2,29k | 755,33k | Automatic Disposition | 320,14 - 333,94 | 9,44k | -19,49% |
| 2026-04-02 | Ms. Melissa McLaughlinChief HR Officer | -8,00 | 2,60k | Vente | 325,49 | 9,44k | -0,08% |
| 2026-04-02 | Ms. Melissa McLaughlinChief HR Officer | -1,62k | 516,41k | Vente | 316,61 - 323,64 | 9,44k | -14,61% |
| 2026-03-04 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -4,71k | 1,52M | Vente | 319,03 - 326,08 | 16,46k | -22,26% |
| 2026-03-04 | Mr. Jeffrey V. PoultonCFO & Exec. VP | -2,47k | 797,35k | Vente | 319,03 - 325,67 | 44,44k | -5,26% |
| 2026-03-04 | Dr. Yvonne L. GreenstreetCEO & Director | -2,93k | 947,58k | Vente | 319,03 - 325,67 | 62,36k | -4,49% |
| 2026-03-04 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -633,00 | 204,51k | Vente | 319,03 - 325,67 | 14,84k | -4,09% |
| 2026-03-05 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -658,00 | 213,18k | Automatic Disposition | 321,81 - 326,24 | 14,84k | -4,25% |
| 2026-03-04 | Mr. Tolga TangulerExec. VP & Chief Commercial Officer | -2,31k | 745,98k | Vente | 319,03 - 325,67 | 18,52k | -11,09% |
| 2026-03-02 | Mr. Jeffrey V. PoultonCFO & Exec. VP | -2,21k | 722,80k | Vente | 323,62 - 332,64 | 41,86k | -5,01% |
| 2026-03-02 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -1,72k | 562,59k | Vente | 323,62 - 332,64 | 3,60k | -32,31% |
| 2026-03-02 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -1,60k | 523,58k | Vente | 323,62 - 332,64 | 16,13k | -9,02% |
| 2026-03-03 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -1,78k | 567,55k | Automatic Disposition | 316,74 - 321,50 | 3,60k | -33,04% |
| 2026-03-03 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -1,65k | 528,19k | Automatic Disposition | 316,55 - 321,58 | 16,13k | -9,29% |
| 2026-03-02 | Mr. Tolga TangulerExec. VP & Chief Commercial Officer | -1,60k | 523,58k | Vente | 323,62 - 332,64 | 16,12k | -9,02% |
| 2026-03-02 | Dr. Yvonne L. GreenstreetCEO & Director | -6,80k | 2,23M | Vente | 323,62 - 332,64 | 59,31k | -10,28% |
| 2026-02-27 | Mr. Jeffrey V. PoultonCFO & Exec. VP | 1,91k | 0,00 | Derivative Exercise and Retained Stock | - | 41,49k | 4,82% |
| 2026-02-27 | Dr. Yvonne L. GreenstreetCEO & Director | 5,92k | 0,00 | Derivative Exercise and Retained Stock | - | 58,19k | 11,33% |
| 2026-02-27 | Mr. Tolga TangulerExec. VP & Chief Commercial Officer | 1,67k | 0,00 | Derivative Exercise and Retained Stock | - | 16,13k | 11,52% |
| 2026-02-27 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -1,91k | 630,80k | Derivative Exercise and Sale | 328,92 - 330,73 | 5,51k | - |
| 2026-02-27 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -2,72k | 902,30k | Automatic Disposition | 330,73 - 334,39 | 5,51k | -33,06% |
| 2026-02-13 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -2,24k | 695,20k | Vente | 310,08 | 6,32k | -26,19% |
| 2026-02-13 | Dr. Yvonne L. GreenstreetCEO & Director | -6,96k | 2,16M | Vente | 310,08 | 46,35k | -13,05% |
| 2026-02-13 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -1,96k | 607,45k | Vente | 310,08 | 10,17k | -16,16% |
| 2026-02-17 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -2,04k | 677,53k | Automatic Disposition | 331,96 | 10,17k | -16,72% |
| 2026-02-13 | Mr. Tolga TangulerExec. VP & Chief Commercial Officer | -1,96k | 607,45k | Vente | 310,08 | 12,80k | -13,28% |
| 2026-02-13 | Mr. Jeffrey V. PoultonCFO & Exec. VP | -2,24k | 695,20k | Vente | 310,08 | 37,67k | -5,62% |
| 2026-01-12 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -1,51k | 547,93k | Vente | 353,95 - 377,82 | 3,98k | -27,50% |
| 2026-01-12 | Dr. Yvonne L. GreenstreetCEO & Director | -9,58k | 3,48M | Vente | 353,95 - 377,82 | 39,10k | -19,68% |
| 2026-01-12 | Mr. Jeffrey V. PoultonCFO & Exec. VP | -2,78k | 1,01M | Vente | 353,95 - 377,82 | 35,34k | -7,29% |
| 2026-01-12 | Mr. Tolga TangulerExec. VP & Chief Commercial Officer | -1,51k | 547,93k | Vente | 353,95 - 377,82 | 10,76k | -12,31% |
| 2026-01-12 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -1,51k | 547,93k | Vente | 353,95 - 377,82 | 10,17k | -12,93% |
| 2026-01-13 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -2,29k | 848,06k | Automatic Disposition | 367,52 - 374,33 | 10,17k | -18,38% |
| 2025-11-26 | Dr. Yvonne L. GreenstreetCEO & Director | 3,58k | 345,32k | Derivative Exercise and Retained Stock | 85,00 - 119,13 | 29,67k | 13,70% |
| 2025-11-26 | Dr. Yvonne L. GreenstreetCEO & Director | -1,12k | 344,54k | Derivative Exercise and Sale | 118,05 - 445,12 | 29,67k | - |
| 2025-11-17 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -8,16k | 2,69M | Derivative Exercise and Sale | 119,13 - 449,00 | 10,17k | - |
| 2025-11-17 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -3,97k | 1,82M | Automatic Disposition | 449,00 - 463,08 | 10,17k | -28,07% |
| 2025-11-12 | Dr. Yvonne L. GreenstreetCEO & Director | -25,65k | 8,61M | Derivative Exercise and Sale | 42,22 - 458,42 | 26,09k | - |
| 2025-10-02 | Dr. Yvonne L. GreenstreetCEO & Director | -8,92k | 4,03M | Vente | 446,53 - 457,64 | 26,09k | -25,48% |
| 2025-10-02 | Mr. Jeffrey V. PoultonCFO & Exec. VP | -3,82k | 1,73M | Vente | 446,53 - 457,64 | 31,92k | -10,69% |
| 2025-10-02 | Mr. Tolga TangulerExec. VP & Chief Commercial Officer | -1,41k | 635,13k | Vente | 446,53 - 457,64 | 8,47k | -14,23% |
| 2025-10-02 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -2,44k | 1,10M | Vente | 446,53 - 457,64 | 14,13k | -14,73% |
| 2025-10-02 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -2,94k | 1,33M | Vente | 446,53 - 457,64 | 1,69k | -63,48% |
| 2025-10-03 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -3,02k | 1,36M | Automatic Disposition | 449,99 - 454,37 | 1,69k | -64,13% |
| 2025-09-09 | Ms. Colleen Foley ReitanIndependent Director | -18,00k | 6,61M | Derivative Exercise and Sale | 100,65 - 480,98 | 775,00 | - |
| 2025-08-29 | Mr. Tolga TangulerExec. VP & Chief Commercial Officer | -3,47k | 1,56M | Automatic Disposition | 445,53 - 452,49 | 7,02k | -33,10% |
| 2025-08-18 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -1,40k | 632,76k | Vente | 447,98 - 455,82 | 1,69k | -45,24% |
| 2025-08-19 | Dr. Pushkal P. GargExec. VP & Chief Research & Development Officer | -1,46k | 666,99k | Automatic Disposition | 455,41 - 461,74 | 1,69k | -46,26% |
| 2025-08-18 | Mr. Jeffrey V. PoultonCFO & Exec. VP | -2,27k | 1,03M | Vente | 447,98 - 455,82 | 27,99k | -7,51% |
| 2025-08-18 | Mr. Tolga TangulerExec. VP & Chief Commercial Officer | -1,40k | 632,76k | Vente | 447,98 - 455,82 | 10,50k | -11,74% |
| 2025-08-18 | Dr. Kevin Joseph FitzgeraldExec. VP, Chief Scientific Officer and Head of Early Research & Early Development | -1,40k | 632,76k | Vente | 447,98 - 455,82 | 11,62k | -10,72% |
| 2025-08-18 | Dr. Yvonne L. GreenstreetCEO & Director | -6,98k | 3,16M | Vente | 447,98 - 455,82 | 22,83k | -23,41% |
| 2025-08-18 | Mr. Michael Weston BonneyInitié | -11,25k | 4,27M | Derivative Exercise and Sale | 70,20 - 450,00 | 20,03k | - |
| 2025-08-14 | Dr. Dennis Arthur AusielloMember of the Scientific Advisory Board & Independent Director | -31,45k | 9,60M | Derivative Exercise and Sale | 72,01 - 442,66 | 3,64k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
